RA Care Should be Guided by Need—Not Age

1 July 2025

Dive into 4 hypothetical case studies that reveal the diverse and often complex presentations of giant cell arteritis (GCA). Each case is guided by expert commentary from Dr Michael Putman, where he offers practical insights and clinical pearls to enhance your therapeutic strategies for this multifaceted condition.

The Value of Kidney Biopsy in Autoimmune Diseases

A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stres

Tweet Author

RheumNow

Tweet Content

A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n

HLA-B27 Testing in Practice A single center study shows HLA-B27 testing is often performed by both by rheumatologists a

Tweet Author

RheumNow

Tweet Content

HLA-B27 Testing in Practice A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined. https://t.co/oq7GNhzwZd

ARD's Impact Factor The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal?

Tweet Author

RheumNow

Tweet Content

ARD's Impact Factor The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

Tweet Author

RheumNow

Tweet Content

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns Pregnancy in patients with systemic lupus erythematosus (SLE) c

Tweet Author

RheumNow

Tweet Content

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population. https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO

Links

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns | RheumNow https://buff.ly/Ul4w2yK

TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in

Tweet Author

RheumNow

Tweet Content

TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) ?

Tweet Author

RheumNow

Tweet Content

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN 3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/jEv2uvhkqK

Links

Lupus Nephritis Treatment Advances: New Therapies on the Horizon Promise Better… https://buff.ly/eaO00Ug

Topics

RA Care Should be Guided by Need—Not Age

The Value of Kidney Biopsy in Autoimmune Diseases

A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stres

HLA-B27 Testing in Practice A single center study shows HLA-B27 testing is often performed by both by rheumatologists a

ARD's Impact Factor The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal?

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns Pregnancy in patients with systemic lupus erythematosus (SLE) c

TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) ?

Do you get our email newsletter?